Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants

KCL-286 is a drug being developed to help treat spinal cord injuries by encouraging nerve cells to regrow. This study checks if KCL-286 is safe for humans. The study involved giving KCL-286 to healthy male volunteers to see how well they tolerated the drug, how it moved through their bodies, and if it affected the intended target in the body. The results showed that KCL-286 was generally well-tolerated and that it did interact with its target receptor in white blood cells, suggesting it could potentially work as intended in spinal cord injury patients.

• 1
  KCL-286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models.
• 2
  Target engagement shows the drug candidate activates its receptor.
• 3
  These findings support further development of KCL-286 as a novel oral treatment for SCI.